This “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Understanding
Acute Lymphoblastic Leukemia (ALL) also known as acute lymphocytic leukemia is a type of blood cancer that affects the lymphocytes a category of white blood cells and starts in the bone marrow (the soft tissue inside certain bones), the site for hematopoiesis. ALL progress rapidly, invade blood stream and spread to other organs such as liver, spleen, lymph nodes. ALL is prevalent in both children and adults. Exposure to radiations, hazardous chemicals such as benzene, and T-lymphocyte infection can raise the risk for ALL. Chimeric Antigen Receptor (CAR) T- Cell therapy which make use of reengineered T cells to produce chimeric antigen receptor on cell surface to recognize and attack cancerous cells with specific antigen. This therapy has shown draconian success in the field of anti-tumor immunotherapy specifically for the treatment of B-cell malignancies.
"CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape is provided which includes the disease overview and CAR T-Cell Therapy for Acute Lymphoblastic Leukemia treatment guidelines. The assessment part of the report embraces, in depth CAR T-Cell Therapy for Acute Lymphoblastic Leukemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-Cell Therapy for Acute Lymphoblastic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Acute Lymphoblastic Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-Cell Therapy for Acute Lymphoblastic Leukemia.
This segment of the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Humanized CAR T-cells targeting CD7 are being developed by PersonGen Therapeutics. In Phase I/II clinical study the patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory acute leukemia.
Obe-cel (AUTO1) is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, obe-cel may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the ability of the programmed T cells to engage in serial killing of target cancer cells. Obe-cel is currently being evaluated in a Phase I/II clinical trial in adult ALL.
Yake biotechnology is currently developing and investigating CAR-T cells targeting CD19 and CD22 in Phase I/II stage of development for the treatment of patients with B-cell acute lymphoblastic leukemia.
This segment of the report provides insights about the different CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 20+ key companies which are developing the therapies for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia. The companies which have their CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drug candidates in the most advanced stage, i.e. Phase I/II include, PersonGen BioTherapeutics.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Acute Lymphoblastic Leukemia therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 3-5 business days.
Geography Covered
- Global coverage
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Understanding
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview
Acute Lymphoblastic Leukemia (ALL) also known as acute lymphocytic leukemia is a type of blood cancer that affects the lymphocytes a category of white blood cells and starts in the bone marrow (the soft tissue inside certain bones), the site for hematopoiesis. ALL progress rapidly, invade blood stream and spread to other organs such as liver, spleen, lymph nodes. ALL is prevalent in both children and adults. Exposure to radiations, hazardous chemicals such as benzene, and T-lymphocyte infection can raise the risk for ALL. Chimeric Antigen Receptor (CAR) T- Cell therapy which make use of reengineered T cells to produce chimeric antigen receptor on cell surface to recognize and attack cancerous cells with specific antigen. This therapy has shown draconian success in the field of anti-tumor immunotherapy specifically for the treatment of B-cell malignancies.
"CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape is provided which includes the disease overview and CAR T-Cell Therapy for Acute Lymphoblastic Leukemia treatment guidelines. The assessment part of the report embraces, in depth CAR T-Cell Therapy for Acute Lymphoblastic Leukemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-Cell Therapy for Acute Lymphoblastic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Acute Lymphoblastic Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-Cell Therapy for Acute Lymphoblastic Leukemia.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Emerging Drugs Chapters
This segment of the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Emerging Drugs
Humanized CD7 CAR-T cells: PersonGen BioTherapeutics
Humanized CAR T-cells targeting CD7 are being developed by PersonGen Therapeutics. In Phase I/II clinical study the patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory acute leukemia.
AUTO 1: Autolus
Obe-cel (AUTO1) is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, obe-cel may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the ability of the programmed T cells to engage in serial killing of target cancer cells. Obe-cel is currently being evaluated in a Phase I/II clinical trial in adult ALL.
CAR-T cells targeting CD19 and CD22: Yake Biotechnology
Yake biotechnology is currently developing and investigating CAR-T cells targeting CD19 and CD22 in Phase I/II stage of development for the treatment of patients with B-cell acute lymphoblastic leukemia.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Therapeutic Assessment
This segment of the report provides insights about the different CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
There are approx. 20+ key companies which are developing the therapies for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia. The companies which have their CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drug candidates in the most advanced stage, i.e. Phase I/II include, PersonGen BioTherapeutics.
Phases
This report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Acute Lymphoblastic Leukemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Report Insights
- CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs?
- How many CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and their status?
- What are the key designations that have been granted to the emerging drugs?
This product will be delivered within 3-5 business days.
Table of Contents
IntroductionExecutive Summary
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Drug Name; Company Name
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
Humanized CD7 CAR-T cells: PersonGen BioTherapeutics
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I)
- Comparative Analysis
pCAR-19B cells: Chongqing Precision Biotech
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Key Companies
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Key Products
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia- Unmet Needs
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia- Market Drivers and Barriers
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia- Future Perspectives and Conclusion
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Analyst Views
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Key Companies
AppendixList of Tables
Table 1 Total Products for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Wuhan Sian Medical Technology Co., Ltd
- Wugen, Inc.
- Yake Biotechnology Ltd.
- Autolus Limited
- Chongqing Precision Biotech Co., Ltd
- Hebei Senlang Biotechnology Inc., Ltd.
- Sabz Biomedicals
- Shenzhen BinDeBio Ltd
- Hrain Biotechnology
- Juventas Cell Therapy Ltd.
- Gracell Biotechnology
- Fate Therapeutics
- Miltenyi Biotec
- CASI Pharmaceuticals
- PersonGen BioTherapeutics
- Shanghai Unicar-Therapy Bio-medicine Technology
